AMRN Dec 2024 2.000 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.9000 |
| Strike | 2.00 |
| Expire Date | 2024-12-20 |
| Day's Range | 0.0500 - 0.0700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 56 |
GlobeNewswireAmarin Announces Two Upcoming Investor Events
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced two important near-term corporate events: [I] Third Quarter 2024 Financial Results – October 30 – The Company will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, immediately following the c
Simply Wall St.Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Sp
